Vertex's Telaprevir Slides By Advisory Committee, But Panelists Want Limits On Some Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
While the committee unanimously endorsed the protease inhibitor for approval, some panelists question whether there is sufficient data to support response-guided therapy for prior-relapse patients.
You may also be interested in...
Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities
For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir
In what is poised to be one of the biggest marketing battles of the year, as Merck's Victrelis (boceprevir) and Vertex's Incivek (telaprevir) close in upon approval, how FDA handles different subgroups of hepatitis C patients in labeling for each of the protease inhibitors could be a determining factor.
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir
In what is poised to be one of the biggest marketing battles of the year, as Merck's Victrelis (boceprevir) and Vertex's Incivek (telaprevir) close in upon approval, how FDA handles different subgroups of hepatitis C patients in labeling for each of the protease inhibitors could be a determining factor.